Radiology Medical News about Radiotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Small hepatocellular carcinoma: Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?
Radiology, 07/02/09

Shibata T et al. - In a study to prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for treatment of small (3 cm) hepatocellular carcinomas (HCCs), it appears that combined radiofrequency ablation plus TACE and radiofrequency ablation alone have equivalent effectiveness for treatment of small HCCs, so the combination treatment may not be necessary.

Methods

89 pts with 93 HCC nodules 0.8–3.0 cm in diameter were randomly treated with combined radiofrequency ablation and TACE (46 pts with 49 nodules) or with radiofrequency ablation alone (43 pts with 44 nodules).
Patients were followed up for 9–68 mos.
Rates of local tumor progression (LTP), overall survival (OS), local progression-free survival (PFS), and event-free survival (EFS) were evaluated by using the Kaplan-Meier method.

Results

1-, 2-, 3-, and 4-yr rates of LTP, OS, local PFS, and recurrence-free survival were as follows: LTP rates were 14.4%, 17.6%, 17.6%, and 17.6%, respectively, in combined treatment group and 11.4%, 14.4%, 14.4%, and 14.4%, respectively, in radiofrequency ablation group.
OS rates were 100%, 100%, 84.8%, and 72.7%, respectively, in combined treatment group and 100%, 88.8%, 84.5%, and 74.0%, respectively, in radiofrequency ablation group.
Local PFS rates were 84.6%, 81.1%, 69.7%, and 55.8%, respectively, in combined treatment group and 88.4%, 74.1%, 74.1%, and 61.7%, respectively, in radiofrequency ablation group.
EFS rates were 71.3%, 59.9%, 48.8%, and 36.6%, respectively, in combined treatment group and 74.3%, 52.4%, 29.7%, and 29.7%, respectively, in radiofrequency ablation group.

<< Previous
Detection of nodal metastatic disease in patients with non-small...

Next >>
An Alternative Echocardiographic Method to Estimate Mean...

Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial
The Lancet Oncology - Online First, 10/30/09 Relevance Score: 96%

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09 Relevance Score: 95%

Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer
Cochrane Reviews, 10/09/09 Relevance Score: 95%

Avoidance of radiotherapy-related, gastrointestinal complications in a patient with systemic lupus erythematosus: A case report and review of literature
Saudi Journal of Gastroenterology, 10/05/09 Relevance Score: 91%

Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma
Annals of Oncology, 11/19/09 Relevance Score: 89%